FDA appoints permanent heads of drug, biologics and tobacco centers and adds AI deputy commissioner

The U.S. Food and Drug Administration announced permanent appointments for the leaders of its major product centers.

The Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research now have permanent directors after serving in acting capacities.

The agency also introduced a new deputy commissioner for technology and artificial intelligence to guide the use of AI in regulatory processes.

These appointments are intended to provide stable leadership and support the FDA’s ongoing modernization initiatives.